People are using new drugs like Ozempic, Mounjaro and Wegovy to lose weight. As david_wainer explains, drug makers Eli Lilly and Novo Nordisk are working to increase insurance coverage and capacity. WSJWhatsNow
Whether the leading companies making this new class of drugs known as GLP-1s can keep up with demand and convince insurers of the wider benefit to patients’ health is now a closely watched
question. Shares of Eli Lilly and Novo Nordisk , the two leading manufacturers of these new drugs, were both down on Thursday as Lilly’s financial results came up short of hyped-up expectations.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eli Lilly’s stock falls after Q4 revenue missEli Lilly & Co.’s stock fell 2.3% before market open Thursday after the biopharmaceutical giant’s fourth-quarter revenue came in below analysts’...
Lire la suite »
Jim Cramer's Investing Club meeting Thursday: Meta, Eli Lilly, Estee LauderInvesting Club: 3 investing lessons from the Club’s meeting Thursday: Meta, Eli Lilly, Estee Lauder
Lire la suite »
Federation Studios’ ‘Kids in Crime’ Wins Kenneth Karlstad the 2023 Nordisk Film & TV Fond Prize“Kids in Crime,” a high energy 22-minute episode coming of age drama with a notable turn by Scandi superstar Jakob Oftebro (“Kon Tiki,” “Black Crab”) as a not-to-be-messed-with local drug lord, wal…
Lire la suite »
Amgen revenue falls slightly as Lilly COVID deal contributes lessAmgen Inc on Tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture COVID-19 antibody treatments for Eli Lilly and Co.
Lire la suite »
Michael Blackson Calls Nephew Eli Apple 'Savage,' 'Runs In The Family'Michael Blackson says his nephew Eli Apple's trash-talking 'runs in the family.'
Lire la suite »
Lilly's ambitious diabetes drug Mounjaro fails to impress in the fourth quarterThe new Type 2 diabetes treatment may be in high demand, but sales came in far below Wall Street’s expectations.
Lire la suite »